Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of the Rheumatic Diseases

Topics

Computer Science

Immunology

Medicine

Pathology

Dermatology

Show all topics

DOI

10.1136/ard-2024-225686

License

CC-BY-NC

Other Formats

PDF